NNNNNNNNNNNNNNNN
SEAnews SEA Research, BLK 758 Yishun Street 72 #09-444 Singapore 760758
India Front Line Report
SEAnews Issue:monthly
tel:65-87221054
NNNNNNNNNNNNNNN
2014-05-09 ArtNo.45013
◆Novartis-GSK-Eli Lilly deal may affect Indian market
【New Delhi】Swiss drug major Novartis' multi-billion-dollar overhaul through deals with two multinational firms — GlaxoSmithKline (GSK) and Eli Lilly — is likely to have an impact on the Indian market, too, as all the three companies have significant presence in the country, primarily in the segments involved in the transaction.
 On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion. Besides, Novartis will pay up to $1.5 billion more if certain milestones are met. It will also form a consumer health joint venture, in which GSK, with an equity interest of 63.5 per cent, will have majority control. Novartis has also agreed to sell its animal health arm to Eli Lilly for about $5.4 billion.
○Pfizer, AstraZeneca shares climb up amidst deal talks
【MUMBAI】Shares of the Indian subsidiaries of Pfizer and AstraZeneca ruled strong for the second successive day, after reports of a possible acquisition of AstraZeneca by Pfizer did the rounds.
 UK's Sunday Times had reported that Pfizer had made a $100-billion offer to take over AstraZeneca, which, in the last few years, has been struggling to register profits owing to the patent expiry of many of its blockbuster drugs.
 The two drugmakers declined to confirm the development, even as the news sent market punters to bet on the likely impact on its Indian subsidiaries. While the shares of AstraZeneca gained 5.3% in two days to end Tuesday's trading at Rs 1109.80 a share, Pfizer gained 5% during the period to end at 1294.55 a share on Tuesday.
【News source】

Novartis-GSK-Eli Lilly deal may affect Indian market

GlaxoSmithKline swaps oncology for vaccines with Novartis AG

Pharma giants Novartis, GSK swap assets in $23-b deal

Pfizer, AstraZeneca shares climb up amidst deal talks

Your Comments


[Your Comments / Unsubscribe]/[您的意见/退订]/[ご意見/配信停止]
Please do not directly reply to the e-mail address which is used for delivering the newsletter.
请别用递送新闻的邮件地址而直接回信。
メールをお届けした送信専用アドレスには返信しないで下さい。
SEAnews 掲載記事の無断転載を禁じます。すべての内容は日本の著作権法並びに国際条約により保護されています。
Copyright 2003 SEAnews® All rights reserved. No reproduction or republication without written permission.